Skip to main content

Applications Open for 2022 CSL Centenary Fellowships

$2.5 Million Funding Available to Australian Biomedical Researchers

news

Melbourne, Australia: 01.06.2021: Australia’s top biomedical researchers are invited to apply for one of two CSL Centenary Fellowships worth $1.25 million over five years in support of discovery and translational medical research.

Applications are now open for the 2022 Fellowships, which are offered to outstanding mid-career (4-10 years post-doctoral) scientists seeking to undertake world-class medical research at an Australian academic institute.

In 2016, in celebration of the company’s 100-year anniversary, CSL established a flagship $25 million fellowship program to champion excellence in early stage translational research.

As well as paying tribute to CSL’s origins, the fellowships are an integral part of how CSL delivers on our promise to foster a thriving medical research community by supporting the development of Australian science.

“Following a year of news lead by the COVID-19 pandemic, biomedical science has further demonstrated its importance and ability to save and improve people’s lives,” said Dr Andrew Nash, CSL’s Chief Scientific Officer and Head of Research.

“Australia is home to CSL’s global hub for early research and translational medicine. We are honoured to be able to support Australian scientists with these fellowships and contribute to the future success of Australia’s R&D and biomedical research community.” said Dr Nash.

There are now 10 active CSL Centenary Fellows. Currently, the Fellows work at the QIMR Berghofer Institute, the Queensland Brain Institute, the Peter MacCallum Cancer Centre, Baker Heart and Diabetes Institute, Monash University, Murdoch Children’s Research Institute, Menzies School of Health Research, South Australian Health and Medical Research Institute, Walter and Eliza Hall Institute of Medical Research and the John Curtin School of Medical Research.

The work of the Fellows is wide ranging, from addressing key questions of fundamental biology through to a better understanding of disease pathogenesis and the development of new approaches to diagnosis and treatment.

The winners of the 2022 CSL Centenary Fellowships will be announced on 27th October 2021 in conjunction with the annual conference of the Australian Academy of Health and Medical Sciences.  

For more information, including application details, visit: www.cslfellowships.com.au

- ends -

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our two businesses, CSL Behring and Seqirus – provides life-saving products to more than 70 countries and employs more than 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit Vita at CSLBehring.com/Vita and follow us on Twitter.com/CSL

For more information about CSL Limited, visit www.csl.com